4 Conclusion
VEGFR TKIs are promising therapeutics for multiple solid cancers. However, all these molecular targeting agents are associated with a variety of adverse events that can impact patients’ quality of life. Here, we report a rare and severe case of apatinib-induced BP, which demonstrated the effectiveness of glucocorticoid therapy for DIBP.